

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

Title: Ongoing outbreak of COVID-19 in Iran: challenges and signs of concern with under-reporting of prevalence and deaths

Authors: Mahan Ghafari,^{1*} Bardia Hejazi,² Arman Karshenas,³ Stefan Dascalu,^{1,4} Alireza Kadvidar,⁵ Mohammad A. Khosravi,⁶ Maryam Abbasalipour,⁶ Majid Heydari,⁷ Sirous Zeinali,^{6,8} Luca Ferretti,⁹ Alice Ledda,¹⁰ Aris Katzourakis^{1*}

Affiliations:

¹ Department of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.

² Department of Physics, Wesleyan University, Middletown, Connecticut, USA.

³ Department of Engineering, University of Oxford, Oxford, UK.

⁴ Avian Influenza Virus, The Pirbright Institute, Woking, UK.

⁵ Center for Statistical and Operational Research, Statsminutes Company, Tehran, Iran.

⁶ Kawsar Human Genetic Research Center, Kawsar Biotech Company, Tehran, Iran.

⁷ Editorial board, Donya-e-Eqtasad Daily newspaper, Tehran, Iran.

⁸ Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

⁹ Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK.

¹⁰ Department of Infectious Disease Epidemiology, Imperial College London, UK.

* Corresponding author.

Email: mahan.ghafari@zoo.ox.ac.uk (MG); aris.katzourakis@zoo.ox.ac.uk (AK)

One Sentence Summary: We use epidemiological and genetic data to investigate the origins of the SARS-CoV-2 outbreak in Iran and assess the degree of under-reporting in prevalence and deaths.

Abstract:

Many countries with an early outbreak of SARS-CoV-2 struggled to gauge the size and start date of the epidemic mainly due to limited testing capacities and a large proportion of undetected asymptomatic and mild infections. Iran was among the first countries with a major outbreak outside China. Using all genomic sequences collected from patients with a travel link to Iran, we estimate that the epidemic started on 21/01/2020 (95% HPD: 05/12/2019 – 14/02/2020) with a doubling time of 3 days (95% HPD: 1.68 – 16.27). We also show, using air travel data from confirmed exported cases, that from late February to early March the number of active cases across the country were more than a hundred times higher than the reported cases at the time. A detailed province-level analysis of all-cause mortality shows 20,718 (CI 95%: 18,859 – 22,576) excess deaths during winter and spring 2020 compared to previous years, almost twice the number of reported COVID-19-related deaths at the time. Correcting for under-reporting of

39 prevalence and deaths, we use an SEIR model to reconstruct the outbreak dynamics in Iran. Our
40 model forecasted the second epidemic peak and suggests that by 14/07/2020 a total of 9M (CI
41 95%: 118K – 44M) have recovered from the disease across the country. These findings have
42 profound implications for assessing the stage of the epidemic in Iran and shed light on the
43 dynamics of SARS-CoV-2 transmissions in Iran and central Asia despite significant levels of
44 under-reporting.

45 **[Main Text:]**

46 **Introduction**

47 With significant levels of mortality and morbidity, the ongoing pandemic of Coronavirus Disease
48 2019 (COVID-19) continues to have a major impact on many countries around the world [1].
49 First reported cases of COVID-19 in Iran were of two infected individuals in the province of Qom
50 on 19 February. In only a few days, reported cases grew rapidly in almost a dozen provinces (see
51 Movie S1 and Figure 1a) which raised concerns that the virus had already been widespread by the
52 time the first two cases were detected in Qom. By 28 February, WHO reported nearly 100
53 confirmed exported cases of COVID-19 from Iran to several countries [2] while, at the time, the
54 Ministry of Health and Medical Education (MoHME) reported a total of 388 confirmed cases
55 across the country [3]. Some early reports suggested that the first two confirmed cases in Qom,
56 one of the thirty-one provinces of Iran, could have been infected by a merchant who had
57 reportedly travelled from China [4]. However, with COVID-19, identifying the so-called ‘patient
58 zero’ is problematic due to high rates of asymptomatic and pauci-symptomatic infections [5].
59 Indeed, some preliminary analysis by the COG-UK consortium shows that there have likely been
60 more than one thousand unique introductions of the virus into the UK, possibly many of which
61 are from individuals who are asymptomatic or show mild symptoms [6]. Therefore, the most
62 likely route of virus spread from China to Iran, and indeed many other countries, was via
63 asymptomatic travelers. Infected individuals typically show no symptoms for about 5 days [7-9]
64 or sometimes no symptoms at all [10-12], while silently spreading the virus [14]. Using aggregate
65 data from the influenza surveillance networks has been proposed as one of the ways to detect
66 early arrival of SARS-CoV-2 into a country [13]. However, a major flu outbreak in Iran which
67 reportedly stretched from November 2019 to early January 2020 may have conflicted with the
68 early diagnosis of COVID-19 patient across the country, thereby hindering control and diagnosis
69 efforts [15,16].

70 During the early days of the epidemic, Pasteur Institute of Iran (PI) was the primary source of
71 testing suspect COVID-19 cases and had enough resources to perform only a few hundred RT-
72 PCR tests per day. By mid-March, WHO and the Chinese Government delivered several
73 shipments of emergency medical supplies along with more than 200,000 additional test kits which
74 helped with the diagnosis of more hospitalised patients [17]. Nevertheless, some of the
75 preliminary analysis showed that Iran was only reporting less than 10% of its symptomatic cases
76 during its first peak in late March [18,19]. From early April, as the country ramped up its testing
77 capacity, MoHME started to report outpatients and carried out limited levels of contact tracing in
78 several provinces (see Fig. 1b). However, despite the growing testing capacity, since the
79 government announced plans for re-opening high-risk activities in late May, the second peak in
80 new cases emerged and the number of outpatients started to shrink over time. This raised
81 concerns that, like the first peak when hospitals in many provinces were at near maximum
82 capacity, the degree of under-reporting in both prevalence and deaths has raised substantially
83 higher again. Another point of concern is that the rate of false-negative detection of SARS-CoV-2

84 by RT-PCR tests can get significantly higher over time as the delay from the onset of symptoms
85 to testing increases. Therefore, by the time tests are taken from hospitalised cases of COVID-19,
86 there could be typically 3 to 7 days past since the onset of their symptoms and, as a result, a
87 significant portion of their tests (up to 50%) may come out as negative [7,20].

88 In this study, we provide a detailed analysis of the COVID-19 outbreak in Iran. By gathering
89 genetic and air travel data from passengers with a link to Iran, we estimate the start date of the
90 epidemic and its prevalence across the country. Coupling this with the estimated number of
91 excess deaths and other key clinical and epidemiological information, such as the age-stratified
92 infection fatality ratios and delays from onset of infection to death, enables us to reconstruct the
93 full transmission dynamics of COVID-19 despite significant levels of under-reporting in
94 prevalence and deaths.

95 First, we investigate the possibility of data manipulation on reported number of cases and deaths
96 by MoHME using Benford's law. We then use epidemiological and genetic data from air travelers
97 with a travel history to Iran along with the first whole-genome sample obtained from inside the
98 country to determine the start date and early growth rate of the epidemic. Next, we provide a
99 province-level analysis on the pattern of spread during winter and spring, highlighting the degree
100 of under-reporting in both point prevalence and deaths. We also assess the risk of importation of
101 infected individuals from China into the country from January to mid-March 2020. Finally, we
102 evaluate the impact of non-pharmaceutical interventions (NPIs) on the growth rate of the
103 epidemic and use an SEIR model to evaluate its burden on the healthcare system over the course
104 of the outbreak.

105 **Results**

106 *Investigating data manipulations using Benford's law*

107 By comparing the reported prevalence and deaths in several countries with sizable outbreaks from
108 mid-February to early-April, we find that many countries, including Iran, were initially on an
109 exponential growth trajectory (see Fig. 2a and 2b). Depending on the testing strategy of each
110 country, i.e. whether they only test hospitalised patients or also allow testing for outpatients, we
111 would expect the reported death toll to follow the same trend as confirmed cases with a few days
112 of delay. However, since 22 March, after passing a total of 1,000 confirmed deaths, Iran's
113 reported death toll changed course to a linear growth despite the fact that the number of cases
114 were still growing exponentially up to 2 April. This appeared in stark contrast with many other
115 countries with large outbreaks and raised concerns over the credibility of the reports from Iran
116 and possible manipulation of data by MoHME. We investigate the latter using Benford's Law
117 (see Methods section). Fig. 2c shows the distribution of leading digits in reported cases and deaths
118 during the exponential phase of the outbreak (see Fig. 2a and 2b) for Iran, USA, and UK which
119 we compare to the Benford distribution. The result shows that the distribution of leading digits in
120 all the three countries are similar to Benford's distribution and that there is no evidence to suggest
121 a manipulation of data has occurred in any of the examined data sets. It is likely that the apparent
122 discrepancy in MoHME's reported numbers is due to delayed turnaround times at the peak of the
123 outbreak when hospitals in several provinces were at near maximum capacity. Prioritising testing
124 for active cases over post-mortem testing of suspect cases is also likely to have contributed to the
125 observed difference in trends.

126

127 *Origins of the epidemic in Iran: a phylogenetic analysis*

128 Since the virus spread undetected during the initial phase of the Iranian epidemic, no
129 epidemiological information is available for this phase. Molecular epidemiology provides a
130 powerful tool to reconstruct the early epidemic trajectory a posteriori, especially when direct
131 epidemiological data are absent, incomplete or biased. The 16 March report from NextStrain
132 showed that sequences from cases with a travel history to Iran correspond to a distinct clade of
133 SARS-CoV-2 [21] and that they were phylogenetically related to the dominant variant circulating
134 in Wuhan at the time (prototype strain MN908947/SARS-CoV-2/Wuhan-Hu-1) [22] – see Data
135 S1 for the full list of genome metadata used for this analysis. We first construct a maximum
136 likelihood phylogenetic tree of all sequences that were linked to Iran (see Fig. 3a). We then use
137 these genomic sequences to determine the time to the most recent common ancestor (TMRCA) of
138 the sequences and characterise the initial epidemic growth rate in Iran (see Methods section).
139 Consistent with other studies [23,24], our inferred substitution rate is 1.66×10^{-3} (95% Highest
140 Posterior Density (HPD): $2.18 \times 10^{-4} - 3.31 \times 10^{-3}$) per site per year and the exponential growth
141 rate of 82 in units of years, corresponding to a doubling time of around 3 days (95%
142 HPD: 1.68–16.27), which is close to the growth rate in the initial phase of European COVID-19
143 epidemics [56]. The age of the root is placed on 21/01/2020 (95% HPD: 05/12/2019 –
144 14/02/2020), a month earlier than the first reported case.

145 *Estimating the under-reporting of incidence using air-travel data*

146 High levels of under-reporting have been noticed in several countries during the early phase of the
147 COVID-19 pandemic. Such under-reporting creates biases that hinders direct estimates of the
148 actual incidence of the disease and are likely to be present in MoHME's report as well. A more
149 reliable estimate of the size of the Iranian epidemic can be obtained from the number of exported
150 cases detected abroad [57575757]. In late February, a total of 8 internationally exported cases of
151 COVID-19 with direct flights from Iran were detected in Lebanon, UAE, Oman, and Kuwait.
152 Similarly, in early March, an additional 28 cases were identified in China (see Table 1). By
153 finding the approximate number of passengers per week travelling from Iran to these countries,
154 we use a binomial likelihood estimation method (see Methods section) to estimate the nationwide
155 incidence (see Fig. 3b). Our result suggests the number of infectious individuals by 25 February is
156 18,500 (95% CI: 11,400 – 30,700) and 259,500 (95% CI: 199,200 – 356,200) 6 March which is
157 aligned with estimated outbreak size from other studies [25,26] and is more than 100 times higher
158 than confirmed cases that MoHME reported at the time – see the sensitivity analysis on the
159 parameters of our model in Table S2. These estimates also suggest a doubling time of 2.6 days
160 (approximate 95% CI: 2.2-3.3 days), which is remarkably consistent with the range observed in
161 many other countries with major outbreaks (2.5 – 3.5 days). We then use this range of doubling
162 times to extrapolate the number of cases back in time and find 13/01/2020 (05/01/2020 –
163 25/01/2020) to be the approximate start date of the epidemic, which is also well aligned with the
164 estimated root age of our phylogenetic analysis.

165 *Estimating the under-reporting of cumulative deaths using excess mortality data*

166 Given the high levels of under-reporting, excess mortality data represent a more reliable source to
167 estimate COVID-19 related deaths. By analysing the seasonal reports from the National
168 Organization for Civil Registration (NOCR) of Iran on province-level all-cause deaths, we find
169 that four provinces in winter and twenty-six provinces in spring 2020 had significantly higher
170 recorded deaths compared to previous years (see Fig.4a and 4b). During winter, the four

171 provinces in central and northern Iran (Qom, Gilan, Golestan, and Mazandaran) showed a 27%
172 rise in mortality with 3,476 (95% CI: 3,172 – 3,779) deaths in excess of previous years. In spring,
173 our estimates show a 22% increase with a total of 17,242 (95% CI: 15,687 – 18,797) excess
174 deaths in twenty-six provinces compared to previous years. Qom and Gilan, two of the hardest-hit
175 provinces in winter, show a lower percentage of excess deaths in spring possibly indicating that
176 the largest part of their outbreak occurred back in winter while in many other provinces such as
177 Mazandaran, Khuzestan, and Qazvin the excess deaths continued to increase during spring. This
178 is also corroborated by numerous reports from various provinces across the country and is aligned
179 with the fact that the first nationwide epidemic peak occurred in late-March.

180 *Early-stage importation risk from China*

181 The Iranian epidemic was most likely seeded by one or more imported cases flying from China.
182 Given the debate on travel restrictions, it is worth assessing what was the actual early-stage risk of
183 imported cases in Iran. We match the air travel data from infected passengers travelling via flights
184 from Beijing, Shanghai, and Guangdong with the prevalence data from China (see Methods
185 section) and find that the expected number of imported cases to Iran from 22 January to 15 March
186 remained very low, with just one imported case expected across the whole period. The fact that
187 the epidemic took over despite the low number of importations from China and the strong
188 overdispersion in transmissions suggests that infected individuals likely belong to a high-risk sub-
189 group of the population, such as businessmen, politicians, or other individuals who frequently
190 travel to the country and tend to meet a large number of contacts.

191 *Evaluating effectiveness of intervention measures and the dynamics of the outbreak*

192 We first evaluate the effectiveness of key NPIs (see Methods section) implemented on set dates in
193 Iran and their impact on reducing the effective reproduction number, R_t (Table 2 and Figure 5a).
194 Our analyses indicate that while intervention measures, particularly the nationwide lockdown
195 during the New Year's holiday month, were effective in curbing the spread ($R_t < 1$), the
196 reopening of high-risk businesses in May led to the emergence of a new peak of infection across
197 the country ($R_t > 1$). They also suggest that mandatory face covering in public spaces can be
198 effective enough to stop the exponential growth pattern ($R_t < 1$) and reduce the transmission rates
199 by late-July/early-August conditioned on having no other major change in NPIs or social
200 behaviour (e.g. travelling for holidays or mass gatherings) during this time period. The model
201 successfully recreates the nationwide trend of the outbreak with one peak in deaths during late
202 March and a second emerging peak that started back in late May due to relaxed NPI measures
203 (see Figure 5b and 5c). Our model correctly forecasted the resurgence of the second epidemic
204 peak [18]. Also, our estimates for point-prevalence and cumulative deaths are aligned with those
205 we predicted based on air travel and excess mortality. Our results suggest, cumulatively, that 9.04
206 (95% CI: 0.147 – 43.65) million people have recovered and 26.14 (95% CI: 0.53 – 155.22)
207 thousand died as of 14 July 2020. Both the first peak in March and the second peak in July has
208 very likely overwhelmed the healthcare system with approximately 8.70 (95% CI: 0.55 – 85.85)
209 thousand severely ill patients during the peak weeks and 0.474 (95% CI: 0.031 – 4.8) million
210 infectious at the peak of the epidemic (see Data S5). We note the large variation in the results is
211 due to variations in the effective reproduction number, R_t , and its significant impact on the
212 growth dynamics of the epidemic. The upper bound in the simulation results corresponds to an
213 initial reproduction number of $R_t = 5$ in which case most infections and deaths take place during
214 the first peak in late March and R_t never goes below 1 throughout the simulation (population
215 reaches herd-immunity threshold by mid-June) while the lower bound assumes an initial

216 reproduction number $R_t = 2.5$ with a very mild first peak in March after which R_t remains below
217 1 and no second peak will emerge.

218 **Materials and Methods**

219 *Data on aggregate number of cases and deaths*

220 We use the time series data for the number of confirmed cases and deaths (see Data S2) from the
221 John Hopkins University Centre for Systems Science and Engineering COVID-19 GitHub
222 repository (accessed on 04/06/2020). We also obtain time series data on confirmed cases in all the
223 31 provinces of Iran from the ministry of health website (*behdasht.gov.ir*). We note that ministry
224 stopped releasing province data from Mar 23 onward. They also did not release province data on
225 Mar 2 and 3. We obtain mortality statistics from the National Organization for Civil Registration
226 of Iran (*sabteahval.ir*).

227 *Benford's law*

228 Benford's law (BL) defines a probability distribution for the leading digits in a determined set of
229 numbers [27]. The probability that a digit, $d = 1, 2, \dots, 9$, is a leading number is given by
230 $P(d) = \log_{10}(1 + (1/d))$ where numbers with leading digit 1 have the highest probability of
231 appearance and this probability steadily decreases as the starting digit becomes larger. BL is used
232 in a variety of fields such as accounting, trade, and election results to study possible fraud and
233 irregularities with data [28-30] and is also frequently used to assess the quality of epidemiological
234 and clinical data [31-33].

235 In the early phase of an outbreak when the number of reported cases and deaths grow
236 exponentially, a function of the form $2^{t/T}$ exactly obeys the BL distribution, where t is the unit of
237 time (measured in days) and T is the doubling time in new cases/deaths. If we combine two data
238 sets with different growth rates into one larger data set, the numbers in the larger data set still
239 obey the BL distribution. In the context of the COVID-19 outbreak, we can examine possible
240 manipulation of data by comparing the probability distribution of the leading digits in the reported
241 number of cases and deaths from different countries to BL distribution. We note that while this
242 method can be used to test if data manipulation has occurred, it does not provide any information
243 about deliberate absence of data by, for instance, not reporting deaths from certain hospitals.

244 *Phylogenetic analysis*

245 We obtain the first whole-genome sequence of SARS-CoV-2 from inside Iran and collect an
246 additional 20 sequences from cases that flew out of Iran and had their viral genomes determined
247 in other countries. Two of these sequences are epidemiologically linked and cannot be used for
248 the purpose of join-inference of TMRCA and doubling times. Thus, we use the remaining 19
249 whole-genome sequences to infer parameters of the epidemic using the phylogenetic software,
250 BEAST [34]. We use the known sampling times with a Continuous-Time Markov Chain
251 reference prior on the substitution rate, an exponential population coalescent model with a
252 lognormal prior on size (mean=1, SD=2), Laplace prior on growth rate (scale=100), and an
253 HKY+G substitution mode [23,24] and allow the Markov chain Monte Carlo to run for a hundred
254 million steps and discard the first 10% steps as burn-in. Effective sample sizes of all parameters
255 are >1,000 ensuring that they are well-sampled. We also construct the maximum likelihood tree
256 of all sequences using PhyML [35].

257

258 *Estimating the number of active cases using air travel data*

259 We estimate the number of passengers from four of the busiest airports in Iran (Tehran, Mashhad,
260 Isfahan, and Shiraz) who flew to Oman, Lebanon, UAE, Kuwait, and China (see Data S3). We
261 allow for 50% (20% - 100%) of the 55 million residents in provinces near the airports to represent
262 their catchment population size (see Data S4). There is typically 5 (4-6) days of incubation period
263 [7-9,36,37] and an additional 5 (3-7) days of delay from symptom onset to detection [38,39]. We
264 further assume that an additional 45% (30%-55%) of asymptomatic and 15% (10%-25%) mildly-
265 symptomatic cases were among the confirmed exported carriers of COVID-19 [40,41]. Thus, the
266 probability of having an infected individual on board the aircraft is given by $p = Dt / M$, where D
267 is the daily passenger flux, M is the catchment population size, and t is the exposure time which is
268 the sum of incubation period and delay to symptom onset to detection. Finally, to estimate the
269 number of infectious individuals, λ_i , for country, i , with n_i detected cases and probability of
270 successful detection, p_i , we can maximise the likelihood function given by

271
$$L = \arg \max_{\lambda_i} \binom{\lambda_i}{n_i} p_i^{n_i} (1 - p_i)^{\lambda_i - n_i}$$

272 *Estimating seasonal excess mortality*

273 We use the publicly available data from the NOCR which records the all-cause registered deaths
274 in Iran per province per season in Solar Hijri (SH) calendar [42]. We assembled this data for the
275 last 5 years to compare the excess mortality during winter and spring 2020 to previous years.
276 Excess deaths refer to the number of deaths above expected seasonal baseline levels, regardless of
277 the reported cause of death, and can be used as a nonspecific measure of the severity of the
278 epidemic and provide a more accurate measure of its burden on the healthcare system [43]. We
279 analyse the NOCR data from 1394 SH to 1399 SH (from 22 December 2015 to 20 June 2020 in
280 the Gregorian calendar). For each province, we apply a least-square regression model on the
281 seasonal deaths from previous years to find the ‘expected’ seasonal death in 2020 (see Fig. S1 and
282 S2) and then calculate the difference with respect to the observed death toll for each province to
283 find excess mortality (see Table S2 and S3). We attribute excess deaths in those provinces with
284 significant deviations (i.e. three standard deviation units) with respect to their expected seasonal
285 value to COVID-19-related deaths.

286 *Evaluating the importation risk of new cases from China in January*

287 We define the importation risk as the mean number of infectious individuals travelling from
288 China to Iran over the span of approximately three months, from the start of the outbreak in China
289 until mid-March. We assume importations to Iran only occur via air travel from infected areas in
290 China. The main routes of travel to Iran are from airports in Beijing, Shanghai, and Guangdong.
291 We allow a fraction, f , of passengers to come from the Hubei province. To calculate f we take the
292 ratio of total passenger traffic from airports in Hubei to 100 busiest airports across the country
293 according to the 2018 report from the Civil Aviation Administration of China [44]. We further
294 assume that only pre-symptomatic or asymptomatic cases travelled to Iran. The probability that an
295 individual on board the plane is infected can be given by

296
$$p(t) = \sum_{k=0}^{\infty} 10(1 - S(k))i(t+k) / N$$

297 where $i(t)$ is the incidence of cases in a given province at time t , N is the population size of the
298 province, and $S(k)$ is the CDF of the incubation period and is assumed to be log-normally
299 distributed (mean=4.8 days, SD=1.9 days) [37]. The factor 10 is to correct for the true incidence
300 by accounting for an additional 90% unascertained infections before mid-March in China [45].
301 Finally, to calculate the expected number of imported cases from 22 January to 15 March, we
302 have

$$303 \sum_{i=\{Beijing, Shanghai, Guangdong\}} \sum_{t=0}^{53} (1-f)c_i p_i(t) + f c_{Hubei} p_{Hubei}(t) \approx 1$$

304 where $t=0$ corresponds to 22 January and c_i is the average number of passengers flying from
305 province i per day.

306 307 *SEIR model*

308 We use a generalised SEIR model with age-stratified compartments to approximate the dynamics
309 of the epidemic [46]. In this model, susceptible individuals can be exposed to the virus through
310 contact with an infected individual. They then progress towards the infectious stage where they
311 can either recover without hospitalisation or progress towards severe illness that requires
312 hospitalisation. For the latter group, individuals either recover or transition to the ICU stage at
313 which point they either die or return back to the hospitalisation state. The effective reproduction
314 number, R_t , is modelled as a piecewise constant function that changes immediately upon a new
315 NPI. In the absence of mobility data from Iran, we make the assumption that the efficacy of
316 individual interventions from other countries are the same as those implemented in Iran and that
317 they remain constant over time (see Table 2). Other studies have shown broad equivalency in the
318 effect of reductions in different types of mobility and their corresponding impact on R_t [47-49].
319 We note that the dynamics of the epidemic, like any other exponentially growing process, is most
320 sensitive to the growth rate. Thus, we allow for a relatively broad range in basic reproduction
321 number, R_0 , and the efficacy of NPIs to appropriately capture the uncertainties in the dynamics.
322 Furthermore, the model relies on fixed estimates of some epidemiological parameters such as age-
323 stratified infection fatality ratio, latency period, and infectious period based on other studies (see
324 Table 3). The duration of hospital/ICU stay is taken from the 14 March report by MoHME (see
325 Fig. S3) [50], and the simulation start date is based on our analysis of exported cases (see Fig.
326 3b). We assume all infected individuals are immune to reinfection over the course of the
327 simulation.

328 329 **Discussion**

330 Using various clinical, epidemiological, and genetic information, we reconstructed the outbreak
331 of SARS-CoV-2 in Iran in the presence of significant levels of under-reporting of prevalence and
332 deaths. We showed that Benford's law can be used as a statistical test to investigate possible
333 manipulation of reported data during the exponential phase of the epidemic. We then examined
334 the burden of the outbreak on 31 provinces of Iran during winter and spring 2020 using the
335 seasonal excess mortality data. We find that a large number of provinces did not show signals of
336 significant excess mortality in winter further supporting the observation that the outbreak was still
337 at its early stages during this period with only a few hot-spot provinces. We further showed that
338 air travel data from confirmed exported cases acts as a proxy for measuring the number of active
339 cases and that genomic data have the power to provide sensible estimates for the start date of the
340 epidemic and its early doubling times. Phylogenetic analysis, coupled with epidemiological

341 (recent travel to Iran in late February and early March) and clinical data (date of symptom onset),
342 further helped with identification an emergent clade of SARS-CoV-2 linked to cases with a travel
343 history to Iran. The lack of genetic diversity in these samples reflects the early stages of SARS-
344 CoV-2 transmissions within Iran and newly identified sequences from Iran are likely to fall in this
345 clade. Other phylogenetic analyses have shown that these sequences are also closely related to
346 three Chinese strains sampled in mid-January from Hubei, Shandong, and Guangdong
347 (Wuhan/HBCDC-HB-05/2020, Shandong/IVDC-SD-001/2020, and Guangdong/DG-S41-
348 P0056/2020) indicating that the first imported case to Iran likely came from mainland China
349 [21,22]. The overall low importation rate of new cases from China based on incidence data
350 suggests that importation to Iran likely occurred via a high-risk individual with frequent travels to
351 the country.

352 In this study, we found no significant evidence of data manipulations based on Benford's law.
353 However, this test alone cannot be used to rule out some systematic or random patterns of absence
354 of data on case or death counts, e.g. from certain hospitals. The number of confirmed COVID-19
355 cases in each country may vary depending on the transparency to report correct statistics and the
356 capacity of the healthcare system to detect new cases. The latter also depends on the accuracy of
357 laboratory test kits and accessibility of diagnostic and screening tests. Indeed, many countries
358 with limited testing capacities may have to prioritise testing that informs policy decisions, e.g.
359 they may not test suspected cases with mild symptoms or those who are asymptomatic and are a
360 close contact of a confirmed case. As a result, the true number of cases is always many times
361 higher than those reported by the health agencies. In addition, the burden of the epidemic can
362 significantly impact the performance of the healthcare system to properly allocate cause of deaths
363 in individuals with underlying health conditions such as diabetes or heart disease. Therefore,
364 tracking all-cause registered deaths and estimating excess mortality during the outbreak provides
365 a more sensitive measure of COVID-19-associated deaths than would be recorded by counting
366 confirmed or suspect deaths. We note that all-cause deaths may also include factors that are not
367 causally associated with SARS-CoV-2 that might affect death rates such as the circulation of the
368 2019–20 seasonal influenza. According to the United Nations Statistical Division the estimated
369 coverage of registered deaths in Iran is 92% [51] which could potentially be suffering even more
370 from under-counting during the peak of the outbreak when there are likely going to be further
371 delays in death registrations. Also, excess seasonal mortality does not take into account the
372 catalysing role of COVID-19 in deaths among individuals with underlying comorbidities who
373 would have likely died during a particular season even without contracting COVID-19 (as part of
374 the 'background' deaths).

375 Despite integrating multiple sources, our data have many limitations. We investigated air travel
376 data only to countries with direct flights to Iran and discarded information from detected cases in
377 countries such as Qatar and Canada since we were not able to independently verify the fraction of
378 passengers on board the planes who travel from Iran to those countries. Also, given the lack of
379 mobility data from Iran, we were unable to investigate possible international exportation of cases
380 to Afghanistan, Iraq, Syria, Azerbaijan, Turkey, and other countries with a significant flow of
381 ground transportation (i.e. trains, buses, and cars) from Iran. We did not have access to the
382 province-level number of confirmed COVID-19 deaths which is a significant source of
383 information to assess excess deaths in the winter and spring 2020. Also, there is likely extreme
384 heterogeneity in the geographical spread of COVID-19 across the country due to various factors
385 such as demographic structure of the provinces' populations, the pattern of social contacts
386 between age groups, and the quality of healthcare and effectiveness of NPIs in different districts.

387 Our SEIR modelling analysis shows that in the most likely scenario by mid-July only 11% of the
388 population have recovered from the disease which implies that a large fraction of the population is
389 still vulnerable to contracting COVID-19. We also find strong indications that the outbreak was
390 never brought under control since it emerged back in mid-January. This has significant
391 implications both for the likely chance of the virus becoming endemic to the country and its likely
392 return during winter this year which, if coupled with seasonal flu, can significantly overwhelm the
393 hospitals. Furthermore, the continuation of under-reporting in prevalence due to limited testing of
394 suspect cases and tracing their contacts will likely lead to several undetected superspreading
395 events that can spark new outbreaks in different parts of the country making nowcasting and
396 forecasting of the COVID-19 epidemic in Iran extremely challenging.
397

398 **References**

- 399 1. World Health Organization, Coronavirus disease 2019 (COVID-19): situation report, 176,
400 (2020).
- 401 2. WHO Director-General's opening remarks at the media briefing on COVID-19 – 28 February
402 2020 [[Link to the report](#)].
- 403 3. *behdasht.gov*. Retrieved 28 February 2020 [[Link to the report](#)].
- 404 4. Wright, R., How Iran became a new epicenter of the coronavirus outbreak. *The New Yorker*,
405 2020 [[Link to the report](#)].
- 406 5. Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., and Shaman, J., Substantial
407 undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-
408 2). *Science*, **368**, 489-493 (2020).
- 409 6. Pybus, O. G., Rambaut, A., and COG-UK-Consortium, Preliminary analysis of SARS-CoV-2
410 Importation & Establishment of UK Transmission Lineages. *Viroglocal.org* (2020).
- 411 7. Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., et al., Early transmission dynamics in
412 Wuhan, China, of novel coronavirus–infected pneumonia. *New England Journal of Medicine*, **82**,
413 1199-1207 (2020).
- 414 8. Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S.,
415 Reich, N. G., and Lessler, J., The incubation period of coronavirus disease 2019 (COVID-19)
416 from publicly reported confirmed cases: estimation and application. *Annals of internal
417 medicine*, **172**, 577-582 (2020).
- 418 9. Ganyani, T., Kremer, C., Chen, D., Torneri, A., Faes, C., Wallinga, J. and Hens, N., Estimating
419 the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March
420 2020. *Eurosurveillance*, **25**, 2000257 (2020).
- 421 10. Oran, D. P. and Topol, E. J., Prevalence of Asymptomatic SARS-CoV-2 Infection: A
422 Narrative Review. *Annals of Internal Medicine*, M20-3012 (2020).
- 423 11. Buitrago-Garcia, D. C., Egli-Gany, D., Counotte, M., J., Hossmann, S., Imeri, H., Ipekci, A.
424 M., Salanti, G., and Low, N., The Role of Asymptomatic SARS-CoV-2 Infections: Rapid Living
425 Systematic Review and Meta-Analysis. *medRxiv*, 2020.04.25.20079103 (2020).
- 426 12. Bai, Y., Yao, L., Wei, T., Tian, F., Jin, D. Y., Chen, L., and Wang, M., Presumed
427 asymptomatic carrier transmission of COVID-19. *JAMA*, **323**, 1406-1407 (2020).
- 428 13. Silverman, J. D., Hupert, N., Washburne, A. D., Using influenza surveillance networks to
429 estimate state-specific prevalence of SARS-CoV-2 in the United States. *Science Translational
430 Medicine*, **12**, eabc1126 (2020).
- 431 14. Ferretti, L., Wymant, C., Kendall, M., Zhao, L., Nurtay, A., Abeler-Dörner, L., Parker, M.,
432 Bonsall, D. and Fraser, C., Quantifying SARS-CoV-2 transmission suggests epidemic control
433 with digital contact tracing. *Science*, **368**, eabb6936 (2020).
- 434 15. World Health Organization, Influenza situation in the Eastern Mediterranean Region,
435 W11/2020 [[Link to the report](#)].

- 436 16. Ghafari, M., Madani, K., In search of the murder: Making sense of Iran's reported deaths,
437 *Medium* (2020) [[Link to the report](#)].
- 438 17. World Health Organization, WHO ships emergency medical supplies to the Islamic Republic
439 of Iran, 12 March (2020) [[Link to the report](#)].
- 440 18. Ghafari, M., Hejazi, B., Karshenas, A., Dascalu, S., Ferretti, L., Ledda, A., Katzourakis, A.,
441 Ongoing outbreak of COVID-19 in Iran: challenges and signs of concern. *medRxiv*,
442 2020.04.18.20070904 (2020).
- 443 19. Russell, T. W., Hellewell, J., Abbott, S., Jarvis, C. I., van Zandvoort, K., CMMID nCov
444 working group, Flasche, S., Eggo, R. M., Edmunds, W. J., Kucharski, A. J., Using a delay-
445 adjusted case fatality ratio to estimate under-reporting. *Centre for Mathematical Modeling of*
446 *Infectious Diseases Repository*, Last update: 24-07-2020.
- 447 20. Wikramaratna, P., Paton, R. S., Ghafari, M., Lourenco, J., Estimating false-negative detection
448 rate of SARS-CoV-2 by RT-PCR. *medRxiv*, 2020.04.05.20053355 (2020).
- 449 21. Hodcroft, E., Müller, N., Wagner, C., Ilcisin, M., Hadfield, J., Bell, S. M., Neher, R., Bedford,
450 T., Genomic analysis of COVID-19 spread. *Nextstrain Situation Report 2020-03-13* [[Link to the](#)
451 [report](#)].
- 452 22. Eden, J. S., Rockett, R., Carter, I., Rahman, H., De Ligt, J., Hadfield, J., et al., An emergent
453 clade of SARS-CoV-2 linked to returned travellers from Iran. *Virus Evolution*, **6**, veaa027 (2020).
- 454 23. Rambaut, A., Phylogenetic analysis of nCoV-2019 genomes. *Viroglocal.org* (2020).
- 455 24. Boni, M. F., Lemey, P., Jiang, X., Lam, T. T. Y., Perry, B., Castoe, T., et al., Evolutionary
456 origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic.
457 *bioRxiv*, 2020.03.30.015008 (2020).
- 458 25. Tuite, A. R., Bogoch, I. I., Sherbo, R., Watts, A., Fisman, D., and Khan, K., Estimation of
459 coronavirus disease 2019 (COVID-19) burden and potential for international dissemination of
460 infection from Iran. *Annals of Internal Medicine*, **172**, 699-701 (2020).
- 461 26. Zhuang, Z., Zhao, S., Lin, Q., Cao, P., Lou, Y., Yang, L., and He, D., Preliminary estimation
462 of the novel coronavirus disease (COVID-19) cases in Iran: A modelling analysis based on
463 overseas cases and air travel data. *International Journal of Infectious Diseases*, **94**, 29-31 (2020).
- 464 27. Benford, F., The law of anomalous numbers. *Proceedings of the American philosophical*
465 *society*, **78**, 551-572 (1938).
- 466 28. Cerioli, A., Barabesi, L., Cerasa, A., Menegatti, M., and Perrotta, D., Newcomb–Benford law
467 and the detection of frauds in international trade. *Proceedings of the National Academy of*
468 *Sciences*, **116**, 106-115 (2019).
- 469 29. Pericchi, L., and Torres, D., Quick anomaly detection by the Newcomb—Benford Law, with
470 applications to electoral processes data from the USA, Puerto Rico and Venezuela. *Statistical*
471 *science*, **26**, 502-516 (2011).
- 472 30. Durtschi, C., Hillison, W., and Pacini, C., The effective use of Benford's law to assist in
473 detecting fraud in accounting data. *Journal of forensic accounting*, **5**, 17-34 (2004).

- 474 31. Idrovo, A. J., and Manrique-Hernández, E. F., Data Quality of Chinese Surveillance of
475 COVID-19: Objective Analysis Based on WHO's Situation Reports. *Asia-Pacific Journal of*
476 *Public Health*, **32**, 165-167 (2020).
- 477 32. Crocetti, E., and Randi, G., Using the Benford's law as a first step to assess the quality of the
478 cancer registry data. *Frontiers in public health*, **4**, 225 (2016).
- 479 33. Idrovo, A. J., Fernández-Niño, J. A., Bojórquez-Chapela, I., and Moreno-Montoya, J.,
480 Performance of public health surveillance systems during the influenza A (H1N1) pandemic in
481 the Americas: testing a new method based on Benford's Law. *Epidemiology & Infection*, **139**,
482 1827-1834 (2011).
- 483 34. Suchard, M. A., Lemey, P., Baele, G., Ayres, D. L., Drummond, A. J., & Rambaut, A.,
484 Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. *Virus evolution*, **4**,
485 vey016 (2018).
- 486 35. Guindon, S., Dufayard, J. F., Lefort, V., Anisimova, M., Hordijk, W., and Gascuel, O., New
487 algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance
488 of PhyML 3.0. *Systematic biology*, **59**, 307-321 (2010).
- 489 36. He, X., Lau, E. H., Wu, P., Deng, X., Wang, J., Hao, X., et al., Temporal dynamics in viral
490 shedding and transmissibility of COVID-19. *Nature medicine*, **26**, 672-675 (2020).
- 491 37. Bi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., et al., Epidemiology and transmission of
492 COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective
493 cohort study. *The Lancet Infectious Diseases*, 10.1016/S1473-3099(20)30287-5 (2020).
- 494 38. World Health Organization, Novel Coronavirus – Thailand (ex-China). 14 January 2020 [[Link](#)
495 [to the report](#)].
- 496 39. Ministry of Health, Labour and Welfare Japan,
497 新型コロナウイルスに関連した肺炎の患者の発生について (1例目). 16 January 2020
498 [[Link to the report](#)].
- 499 40. Lavezzo, E., Franchin, E., Ciavarella, C., Cuomo-Dannenburg, G., Barzon, L., Del Vecchio,
500 C., et al., Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature*,
501 04.17.20053157 (2020).
- 502 41. Casey, M., Griffin, J., McAloon, C. G., Byrne, A. W., Madden, J. M., McEvoy, D., et al., Pre-
503 symptomatic transmission of COVID-19: a secondary analysis using published data. *medRxiv*,
504 2020.05.08.20094870 (2020).
- 505 42. National Organization for Civil Registration, Registered Deaths by Province. *Sabteahval.ir*
506 (Accessed in June 2020) [[Link to the report](#)].
- 507 43. Olson, D. R., Huynh, M., Fine, A., Baumgartner, J., Castro, A., Chan, H. T., et al.,
508 Preliminary estimate of excess mortality during the COVID-19 outbreak – New York City, March
509 11–May 2, 2020. *CDC MMWR*, **69** (2020).
- 510 44. Civil Aviation Administration of China, 年民航机场生产统计公报. 5 March 2020 [[Link to](#)
511 [the report](#)].
- 512 45. Hao, X., Cheng, S., Wu, D., Wu, T., Lin, X., & Wang, C. (2020). Reconstruction of the full
513 transmission dynamics of COVID-19 in Wuhan. *Nature*, 10.1038/s41586-020-2554-8 (2020).

- 514 46. Noll, N. B., Aksamentov, I., Druelle, V., Badenhorst, A., Ronzani, B., Jefferies, G., Albert, J.,
515 Neher, R., COVID-19 Scenarios: an interactive tool to explore the spread and associated
516 morbidity and mortality of SARS-CoV-2. *medRxiv*, 2020.05.05.20091363 (2020).
- 517 47. Flaxman, S., Mishra, S., Gandy, A., Unwin, H. J. T., Mellan, T. A., Coupland, H., et al.,
518 Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature*,
519 10.1038/s41586-020-2405-7 (2020).
- 520 48. Mellan, T. A., Hoeltgebaum, H. H., Mishra, S., Whittaker, C., Schnekenberg, R. P., Gandy,
521 A., et al., Report 21: Estimating COVID-19 cases and reproduction number in Brazil. *medRxiv*,
522 2020.05.09.20096701 (2020).
- 523 49. Unwin, H., Mishra, S., Bradley, V. C., Gandy, A., Vollmer, M., Mellan, T., et al., Report 23:
524 State-level tracking of COVID-19 in the United States. *Imperial London College Report*,
525 10.25561/79231 (2020).
- 526 50. National Committee on COVID-19 Epidemiology, Daily Situation Report on Coronavirus
527 disease (COVID-19) in Iran. 14 March 2020 [[Link to the report](#)].
- 528 51. United Nations Statistical Division, Demographic and Social Statistics. *unstats.un.org*
529 (Accessed in June 2020) [[Link to the report](#)].
- 530 52. Candido, D. S., Claro, I. M., de Jesus, J. G., Souza, W. M., Moreira, F. R., Dellicour, S., et al.,
531 Evolution and epidemic spread of SARS-CoV-2 in Brazil. *Science*, 10.1126/science.abd2161
532 (2020).
- 533 53. Eikenberry, S. E., Mancuso, M., Iboi, E., Phan, T., Eikenberry, K., Kuang, Y., et al., To mask
534 or not to mask: Modeling the potential for face mask use by the general public to curtail the
535 COVID-19 pandemic. *Infectious Disease Modelling*, **5**, 293-308 (2020).
- 536 54. Surveillances, Vital, The epidemiological characteristics of an outbreak of 2019 novel
537 coronavirus diseases (COVID-19) – China, 2020. *China CDC Weekly*, **2**, 113-122 (2020).
- 538 55. Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., et al., Estimates of
539 the severity of coronavirus disease 2019: a model-based analysis. *The Lancet infectious diseases*,
540 **20**, 669-677 (2020).
- 541 56. Pellis, L., Scarabel, F., Stage, H. B., Overton, C. E., Chappell, L. H., Lythgoe, K. A., et al.,
542 Challenges in control of Covid-19: short doubling time and long delay to effect of
543 interventions. *medRxiv*, 2020.04.12.20059972 (2020).
- 544 57. Imai, N., Dorigatti, I., Cori, A., Donnelly, C., Riley, S., and Ferguson, N., Report 2:
545 Estimating the potential total number of novel Coronavirus cases in Wuhan City, China. *Imperial*
546 *College London COVID-19 Response Team* (2020).
- 547

548 **Acknowledgments: Funding:** MG and SD are funded by the Biotechnology and Biological
549 Science Research Council (BBSRC), grant number BB/M011224/1. **Author contributions:** MG,
550 AL, and AK conceptualised and developed the work. MG wrote the manuscript and all other
551 authors reviewed and edited the manuscript. BH and MG investigates data manipulation and
552 carried out the Benford analysis. AKar collected the air travel data for confirmed exported cases.
553 AKar and MG analysed the air travel data to measure incidence across the country. AKad and
554 MG collected and analysed the excess mortality data. MAK, MA, and SZ collected and validated
555 the genomic sample from Iran. AK and MG collected the remaining 20 genomic sequences from
556 passengers with a travel history to Iran and carried out the phylogenetics analysis. MH and MG
557 collected the data regarding daily reports on testing and set dates for non-pharmaceutical
558 intervention measures. **Competing interests:** Authors declare no competing interests. **Data and**
559 **materials availability:** All data and codes used for the analysis is available online on our GitHub
560 repository (github.com/mg878/Iran_study).

561

562 **Figures:**

563




Fig. 1. Epidemiological and demographic characteristics of confirmed COVID-19 cases in Iran through time. (A) Total incidence of COVID-19 by province on 22 Mar 2020 (last day that MoHME released province-level daily cases). **(B)** Number of confirmed hospitalised patients (dark blue) and outpatients (light blue). Red lines show the number of daily tests taken over time. Vertical arrows indicate some of the major interventions or changes of policies.

564




Fig. 2. Investigating data manipulation on reported number of cases and deaths. (A) and (B) show the number of new cases and deaths over the last seven days with respect to the total number of cases and deaths, respectively. (C) Shows the probability distribution of leading digits in the total number of confirmed cases and deaths from the start of the epidemic in each country during the exponentially growing phase and compare this to the distribution given by Benford's law (BL). We sample 40 random numbers from this data set for each country and count the number of occurrences for the leading digits. To ensure convergence, we repeat this process 50 times. Error bars represent one standard deviation unit away from the mean.

565

566

567




Fig. 3. Phylogenetic and epidemiological analysis on cases with a travel link to Iran. (A) Maximum likelihood phylogenetic tree of samples linked to Iran (including the first sample from inside Iran, HGRC-01-IPI-8206/2020). The labels include the sampling times used in the BEAST analysis. Red labels indicate the two epidemiologically linked samples that were excluded from the subsequent analysis. (B) Estimating the start date of the epidemic and its initial growth trajectory (with a range of doubling times from 2.5 to 3.5 days) based on the likelihood analysis on exported cases to UAE (best case scenario with the lowest estimated number of active cases), Lebanon (worst case scenario with the highest estimated number of active cases), and Kuwait, Oman, and China (see Table 1). The likely scenario is based on the expected number of active cases in late February.

568

569




Fig. 4. Percentage of excess deaths (with respect to the five-year average) during winter and spring 2020 in 31 provinces of Iran. (A) and (B) show the percentage of excess deaths during winter (from 22 Dec 2019 to 19 Mar 2020) and spring (from 20 Mar to 20 June 2020). Four provinces (highlighted in cyan) during winter and twenty-six provinces (highlighted in green) during spring show significant levels of excess mortality. Gray bars represent provinces with no significant deviations from their five-year average (based on 95% confidence interval). The vertical dashed lines show the mean percentage of excess mortality in each season. During winter, the mean excess mortality is only 2% while in spring this grows to 21% across all provinces.

570

571

572




Fig. 5. Reconstructing the epidemic in Iran using an SEIR model. Country-level estimation of infections, deaths, and proportion recovered based on the effect of NPIs on effective reproduction number. **(A)** Time-varying reproduction number, R_t . Vertical dashed lines correspond to the dates when major intervention measures were implemented (see Table 1). **(B)** Shows the weekly number of infections (orange line) and estimated number of infections (orange dots) based on confirmed exported cases (with error bars showing the 95% CI). The number of weekly infections estimated by the model drops immediately after an NPI takes into effect. The weekly number of deaths (brown line) follows the same trend as the reported number of deaths (brown dots). **(C)** Shows the cumulative deaths (purple line) and total number of individuals recovered (green line). The predicted cumulative deaths grow proportionally with respect to cumulative reported deaths (purple dots) and does not reach higher values with respect to the estimated excess mortality during winter and spring (red dots). Lines represent model predictions and shaded areas are 95% confidence intervals.

573 **Tables:**

574 **Table 1. Estimated number of infectious individuals based on air travel data.** This includes a list of all countries
575 with confirmed cases of COVID-19 travelling from Iran via direct flights (see Data S3 for more information).

Date	Country	Passengers/week	Reported cases	Estimated active cases (95% CI)
21/02/2020	Lebanon ¹	800	1	64,000 (19,700 – 236,900)
22/02/2020	UAE ²	13,430	2	7,700 (3,200 – 19,900)
24/02/2020	Oman ³	2,660	2	39,000 (16,100 – 101,000)
25/02/2020	Kuwait ⁴	4,025	3	32,200 (14,400 – 76,000)
06/03/2020	China ⁵	4,500	28	259,500 (199,200 – 356,200)

576 ¹[Source](#), ²[Source](#), ³[Source](#), ⁴[Source](#), ⁵[Source](#)

577

578 **Table 2. Timeline of intervention policy announcements and their impact on effective reproduction number.**

Intervention measures	Description	Date effective [†]	Relative %reduction in Rt (range) [‡]	Reference
School & university closure	Implemented in multiple provinces: Tehran, Mazandaran, Qom, Qazvin, Golestan, Gilan, and several others.	22/02/2020	20% (10-30)	[47]
Nationwide lockdown*	Closure of all schools, universities, sport centres, & holy sites.	05/03/2020	80% (65-90)	[47]
Re-opening of low-risk businesses	Partial re-opening of certain businesses such as banks and governmental agencies with limited staff.	18/04/2020	70% (60-85)	[47,48]
Re-opening of all businesses	Re-opening of all businesses including shops and restaurants while observing social distancing rules	26/05/2020	60% (50-75)	[48,49]
Mandatory face-covering	Mandatory in all public spaces including public transports, restaurants, & shops	05/07/2020	75% (60-90)	[53]

579 *This intervention is followed by the closure of all business across the country due to the Iranian New Year's holiday
 580 period which started in the week leading to 19/03/2020 and has the highest impact on reducing Rt.

581 [†]Older interventions end as soon as a new one takes into effect.

582 [‡]The relative reduction in Rt is based on estimates from European countries, USA, and Brazil.

583

584

585 **Table 3. SEIR model parameters.** We use this information, along with the effectiveness of intervention measures in
586 reducing R_t (Table 1), to run the simulations on *covid19-scenarios.org* dashboard [46].

Age group	Age distribution*	% of all infections that are fatal†	Model parameters	Expected value	Reference
0-9	14,434,000	0.00075	Basic reproduction number	3.75 (2.5-5)	[47-49,52]
10-19	11,812,000	0.0045	Latency period‡	2.5 days	[36,40,41]
20-29	12,254,000	0.009	Infectious period‡	4 days	[36,40,41]
30-39	16,786,000	0.02	Hospital stay	4.5 days	Fig. S3
40-49	11,926,000	0.072	ICU stay	6 days	Fig. S3
50-59	8,281,000	0.25	Imports per day	0	
60-69	5,264,000	1.1	Initial number of cases	1	
70-79	2,264,000	3.1	Simulation start date	13/01/2020	
+80	1,015,000	6.9	Simulation end date	31/08/2020	

587 *based on annual reports on vital statistics from the Statistical Center of Iran (*amar.org.ir*).

588 †We use the statistics from the Chinese CDC [54] for age-stratified IFR which are also broadly compatible with
589 estimates from other studies [55].

590 ‡Latency period is the delay from infection to onset of infectiousness. Infectiousness typically starts from 2.5 days
591 and peaks at 1 day before the onset of symptoms. Together with infectious period, latency period sets the serial
592 interval [46].
593

594 Supplementary Materials:
595

596 **Movies S1. The spread of the COVID-19 epidemic in Iran.** This includes the incidence, total reported cases and
597 deaths in 31 provinces from 19 February to 22 March 2020 (we note that MoHME has not released the province-level
598 data on cases and deaths since 22 March).
599

600 **Data S1. Genome metadata.** We gratefully acknowledge the authors, originating and submitting labs of the
601 sequences from GISAID's Database (*gisaid.org*) on which part of our genetic analysis is based.
602

603 **Data S2. Number of confirmed cases and deaths.** This includes a time series data for the number of confirmed
604 cases and deaths in Iran, UK, US, France, Italy, and Spain as well as daily confirmed cases in Guangdong, Shanghai,
605 Beijing, and Hubei.
606

607 **Data S3. Estimated number of passengers per country per airport.** This includes a detailed list of all flights from
608 airports in Tehran, Isfahan, Shiraz, and Mashhad to Oman, UAE, Kuwait, Lebanon, and China. The list also includes
609 flight numbers which enables us to find the approximate seating capacity based on aircraft model.
610

611 **Data S4. Estimated catchment population size.** This includes the approximate population of 17 provinces that use
612 the 4 airports in Iran for international travels.
613


614 **Data S5. SEIR simulation results.** This includes a detailed output of our SEIR modelling (exported from *covid19-*
615 *scenarios.org* dashboard). The file includes dates, confirmed weekly cases, confirmed weekly deaths, effective
616 reproduction number, severe cases, exposed individuals, infectious individuals, severely ill individuals (hospitalised),
617 individuals in the ICU, weekly fatalities, cumulative recovered, and cumulative fatalities with their corresponding
618 95% CI (upper and lower bounds).
619

620



621 **Fig. S1. Province-level pattern of excess mortality during winter** This record covers every registered death over
622 the last five years including last winter (from 22 December 2019 to 19 March 2020). Gray areas show the 95%
623 confidence interval.
624

625



626 **Fig. S2. Province-level pattern of excess mortality during spring.** This record covers every registered death over
627 the last five years including last spring (from 20 March to 20 June 2020). Gray areas show the 95% confidence
628 interval.
629

630




Fig. S3. Delay from hospitalization to death in Iran. (A) Delay from hospital admission to hospital death [50]. (B) Comparison of delay from hospitalization to hospital death for patients with (red) and without tracheal intubation (black).

631

632

633 **Table S1. SARS-CoV-2 genomes analysed in this study.** A complete metadata with additional information
 634 regarding author list and submitting labs can be found in Data S1.

GISAID ID	Virus name	Location	Collection date	Travel history
EPI_ISL_415583	Canada/BC_40860/2020	Canada	2020-03-03	Travel to Iran
EPI_ISL_413599	Australia/NSW13/2020	Australia	2020-03-04	Travel to Iran
EPI_ISL_412975	Australia/NSW05/2020	Australia	2020-02-28	Travel to Iran
EPI_ISL_413213	Australia/NSW06/2020	Australia	2020-02-29	Travel to Iran
EPI_ISL_413597	Australia/NSW11/2020	Australia	3/2/2020	Travel to Iran
EPI_ISL_413598	Australia/NSW12/2020	Australia	3/4/2020	Travel to Iran
EPI_ISL_412965	Canada/BC_37_0-2/2020	Canada	2020-02-16	Travel to Iran
EPI_ISL_415577	Canada/BC_69243/2020	Canada	2020-02-20	Contact of a case
EPI_ISL_415579	Canada/BC_25211/2020	Canada	3/2/2020	Travel to Iran
EPI_ISL_415587	Canada/BC_66353/2020	Canada	3/4/2020	Travel to Iran
EPI_ISL_415585	Canada/BC_65034/2020	Canada	3/4/2020	Contact of a case
EPI_ISL_415580	Canada/BC_17397/2020	Canada	2020-02-28	Travel to Iran
EPI_ISL_415578	Canada/BC_13297/2020	Canada	2020-02-27	Travel to Iran
EPI_ISL_415581	Canada/BC_02421/2020	Canada	3/1/2020	Travel to Iran
EPI_ISL_413490	NewZealand/01/2020	New Zealand	2020-02-27	Travel to Iran
EPI_ISL_414520	Germany/BavPat2/2020	Germany	3/2/2020	Travel to Iran
EPI_ISL_414476	USA/NY1-PV08001/2020	USA	2020-02-29	Travel to Iran
EPI_ISL_417444	Pakistan/Gilgit1/2020	Pakistan	3/4/2020	Travel to Iran
EPI_ISL_419657	Austria/CeMM0004/2020	Austria	3/3/2020	Travel to Iran
EPI_ISL_414646	Finland/FIN-266/2020	Finland	3/4/2020	Travel to Iran
EPI_ISL_424349	Iran/HGRC-01-IPI-8206/2020	Iran	2020-09-03	First sequence from inside Iran

635
636

637 **Table S2. Sensitivity analysis for the number of active cases based on confirmed exported cases.**

Lebanon (21 Feb)				Catchment population (M= million individuals)			
				min = 11.1M		max = 55.6M	
				Airplane capacity			
				min = 50%	max = 90%	min = 50%	max = 90%
Percentage of undetected pre- & asymptomatics	min = 40%	Exposure time (days)	min = 7	54700 (16700 - 202900)	30000 (8900 - 112300)	277100 (87600 - 1018400)	153500 (48200 - 565400)
			max = 13	29000 (8600 - 108800)	15700 (4300 - 60000)	148800 (46700 - 547900)	82300 (25500 - 304000)
	max = 80%	min = 7	54700 (16700 - 202900)	30000 (8900 - 112300)	277100 (87600 - 1018400)	153500 (48200 - 565400)	
		max = 13	29000 (8600 - 108800)	15700 (4300 - 60000)	148800 (46700 - 547900)	82300 (25500 - 304000)	

638

UAE (22 Feb)				Catchment population (M= million individuals)			
				min = 11.1M		max = 55.6M	
				Airplane capacity			
				min = 50%	max = 90%	min = 50%	max = 90%
Percentage of undetected pre- & asymptomatics	min = 40%	Exposure time (days)	min = 7	5000 (1800 - 14600)	2800 (1000 - 8000)	24800 (9500 - 73200)	13800 (5200 - 40600)
			max = 13	2700 (900 - 7800)	1500 (500 - 4300)	13400 (5100 - 39400)	7400 (2800 - 21800)
	max = 80%	min = 7	6600 (2700 - 17000)	3700 (1500 - 9400)	33100 (14000 - 85500)	18400 (7700 - 47400)	
		max = 13	3600 (1400 - 9100)	2000 (1500 - 5000)	17800 (7500 - 46000)	9900 (4100 - 25500)	

639

640

641

642

Oman (24 Feb)				Catchment population (M= million individuals)			
				min = 11.1M		max = 55.6M	
				Airplane capacity			
				min = 50%	max = 90%	min = 50%	max = 90%
Percentage of undetected pre- & asymptomatics	min = 40%	Exposure time (days)	min = 7	25,100 (9,200 – 74,200)	13,900 (5,100 – 41,200)	125,400 (46,600 – 371,400)	69,700 (25,800 – 206,300)
			max = 13	13,500 (4,900 – 39,900)	7,500 (2,700 – 22,100)	67,500 (25,000 – 199,900)	37,500 (13,900 – 111,000)
	max = 80%	min = 7	33,400 (13,800 – 86,600)	18,600 (7,600 – 48,100)	167,200 (69,200 – 433,400)	92,900 (38,400 – 240,700)	
		max = 13	18,000 (7,400 – 46,600)	10,000 (4,000 – 25,800)	90,000 (37,200 – 233,300)	50,000 (20,600 – 129,600)	

643

Kuwait (25 Feb)				Catchment population (M= million individuals)			
				min = 11.1M		max = 55.6M	
				Airplane capacity			
				min = 50%	max = 90%	min = 50%	max = 90%
Percentage of undetected pre- & asymptomatics	min = 40%	Exposure time (days)	min = 7	5,000 (1,800 – 14,600)	2,800 (1,000 – 8,000)	24,800 (9,500 – 73,200)	13,800 (5,200 – 40,600)
			max = 13	2,700 (900 – 7,800)	1,500 (500 – 4,300)	13,400 (5,100 – 39,400)	7,400 (2,800 – 21,800)
	max = 80%	min = 7	6,600 (2,700 – 17,000)	3,700 (1,500 – 9,400)	33,100 (14,000 – 85,500)	18,400 (7,700 – 47,400)	
		max = 13	3,600 (1,400 – 9,100)	2,000 (1,500 – 5,000)	17,800 (7,500 – 46,000)	9,900 (4,100 – 25,500)	

644

645

646

China (6 Mar)				Catchment population (M= million individuals)			
				min = 11.1M		max = 55.6M	
				Airplane capacity			
				min = 50%	max = 90%	min = 50%	max = 90%
Percentage of undetected pre- & asymptomatics	min = 40%	Exposure time (days)	min = 7	197,700 (149,600 – 277,000)	109,800 (83,100 – 153,800)	988,400 (748,400 – 1,385,300)	549,100 (415,700 – 769,600)
			max = 13	106,400 (80,500 – 149,100)	59,100 (44,700 – 82,800)	532200 (402900 - 745900)	295,700 (223,800 – 414,300)
	max = 80%	min = 7	252,100 (196,400 – 339,100)	140,000 (109,100 – 188,400)	1260300 (982300 - 1696100)	700,100 (545,700 – 942,200)	
		max = 13	135,700 (105,700 – 182,600)	75,400 (58,700 – 101,400)	678,600 (528,900 – 91,3200)	377,000 (293,800 – 507,300)	

647
648
649

650 **Table S2. Excess mortality in 31 provinces during Winter 2020.** This record covers every registered death from 22
 651 December 2019 to 19 March 2020. Provinces with significantly higher excess deaths compared to previous years are
 652 highlighted in cyan.

Province	Expected deaths (regression)	Registered deaths	Excess deaths	%Excess deaths	SD Excess deaths	Excess deaths lower bound (CI 95%)	Excess deaths upper bound (CI 95%)	Significance
Qom	1,583	2,305	723	46%	6	704	741	+
Gilan	4,556	5,937	1,382	30%	86	1,123	1,640	+
Golestan	2,373	2,947	575	24%	30	486	663	+
Mazandaran	4,477	5,274	797	18%	44	666	928	+
Charmahal o Baxtiyari	1,003	1,061	58	6%	50	-91	207	-
Qazvin	1,644	1,728	85	5%	28	0	169	-
Markazi	2,052	2,112	60	3%	89	-208	328	-
Tehran	16,306	16,773	467	3%	399	-731	1,665	-
Isfahan	6,561	6,729	169	3%	212	-467	804	-
Yazd	1,323	1,333	10	1%	18	-43	63	-
Kordestan	1,908	1,912	5	0%	78	-231	240	-
Alborz	3,072	3,070	-2	0%	202	-608	605	-
Hormozgan	1,810	1,799	-11	-1%	105	-326	305	-
North Khorasan	1,243	1,234	-9	-1%	35	-115	97	-
East Azarbaijan	5,811	5,765	-46	-1%	134	-448	356	-
South Khorasan	987	978	-9	-1%	55	-173	156	-
Semnan	962	950	-12	-1%	45	-147	123	-
Kermanshah	2,967	2,899	-68	-2%	115	-412	277	-
Zanjan	1,434	1,396	-38	-3%	84	-291	216	-
Bushehr	1,212	1,178	-34	-3%	28	-117	49	-
Fars	5,994	5,780	-214	-4%	222	-880	453	-
West Azarbaijan	4,198	4,032	-166	-4%	48	-309	-23	+
Hamedan	2,827	2,711	-116	-4%	28	-200	-31	+
Khorasan Razavi	8,168	7,825	-343	-4%	299	-1,240	555	-
Khuzestan	5,809	5,562	-247	-4%	198	-841	347	-
Ardabil	1,864	1,781	-83	-4%	76	-310	144	-
Lorestan	2,418	2,296	-122	-5%	47	-262	19	-
Ilam	706	633	-73	-10%	45	-209	63	-
Kerman	4,166	3,687	-479	-11%	97	-771	-186	+
Kohgilueh o Boyerahmad	810	710	-100	-12%	49	-246	46	-
Sistan o Baluchestan	3,976	3,390	-586	-15%	352	-1,642	470	-

Province	Expected deaths (regression)	Registered deaths	Excess deaths	%Excess deaths	SD Excess deaths	Excess deaths lower bound (CI 95%)	Excess deaths upper bound (CI 95%)
4 Provinces	12,988	16,463	3,476	27%	101	3,172	3,779

653

654

655 **Table S3. Excess mortality in 31 provinces during 2020.** This record covers every registered death from 20 March
 656 to 20 June 2020. Provinces with significantly higher excess deaths compared to previous years are highlighted in
 657 green.

Province	Expected deaths (regression)	Registered deaths	Excess deaths	%Excess deaths	SD Excess deaths	Excess deaths lower bound (CI 95%)	Excess deaths upper bound (CI 95%)	Significance
Qazvin	1,251	2,067	816	65%	103	508	1,123	+
Charmahal o Baxtiyari	766	1,057	291	38%	110	-40	622	-
Kordestan	1,635	2,229	594	36%	207	-27	1,215	-
Mazandaran	4,040	5,449	1,409	35%	65	1,214	1,604	+
Golestan	2,180	2,858	678	31%	95	394	963	+
Khuzestan	4,919	6,395	1,476	30%	242	751	2,201	+
Gilan	4,059	5,258	1,199	30%	38	1,085	1,313	+
Zanjan	1,225	1,585	360	29%	43	232	488	+
Ardabil	1,641	2,105	464	28%	50	314	614	+
Alborz	2,638	3,365	727	28%	47	585	869	+
Isfahan	5,767	7,172	1,405	24%	67	1,204	1,607	+
Tehran	14,421	17,713	3,292	23%	239	2,575	4,008	+
Ilam	573	692	119	21%	14	76	161	+
Qom	1,511	1,823	312	21%	57	141	483	+
Yazd	1,249	1,496	247	20%	30	157	338	+
East Azarbayjan	5,451	6,485	1,034	19%	126	655	1,414	+
North Khorasan	1,083	1,283	200	18%	49	53	347	+
Kermanshah	2,666	3,132	466	17%	111	133	799	+
Lorestan	2,246	2,611	365	16%	47	223	507	+
Hormozgan	1,449	1,681	232	16%	87	-29	493	-
Semnan	844	977	133	16%	33	34	232	+
Markazi	1,933	2,217	284	15%	65	88	479	+
Khorasan Razavi	7,618	8,665	1,047	14%	235	342	1,752	+
West Azarbayjan	3,818	4,338	520	14%	87	258	781	+
Hamedan	2,605	2,940	335	13%	82	90	579	+
Kohgilueh o Boyerahmad	691	755	64	9%	12	28	100	+
South Khorasan	973	1,054	81	8%	18	27	135	+
Bushehr	963	1,033	70	7%	70	-141	280	-
Sistan o Baluchestan	2,750	2,929	179	7%	124	-193	551	-
Kerman	3,268	3,479	211	6%	67	11	411	+
Fars	5,343	5,541	198	4%	123	-172	567	-

Province	Expected deaths (regression)	Registered deaths	Excess deaths	%Excess deaths	SD Excess deaths	Excess deaths lower bound (CI 95%)	Excess deaths upper bound (CI 95%)
26 Provinces	78,672	95,914	17,242	22%	518	15,687	18,797